Is @entity3791 effective in the treatment of XXXX ? A pilot study.

@entity1 @entity227 @entity6 @entity3791 @entity4 @entity1103 @entity6391 @entity941 @entity989
AIM: To investigate whether @entity3791 , already found to be helpful in decreasing @entity1103 in @entity1 with @entity6391 , was also effective in the treatment of @entity1103 in @entity989 . METHODS: Two randomized age- and sex-matched groups (cases and controls) of 12 @entity6 (five Type 1 and seven Type 2) were selected for this pilot study and graded for @entity989 (Early Treatment of @entity6 Study-Airlie House Classification). Cases were treated with @entity3791 for three months according to a standard protocol. The Early Treatment of @entity6 Study chart was used for assessing far-best corrected @entity227 , and @entity941 angiography was performed using the Heidelberg Retina Angiograph. The Amsler grid-test and computerized-perimetry (Octopus 2000R) were also performed. RESULTS: @entity941 -angiographic findings and perimetric data improved significantly (p < 0.01) in the @entity3791 -treated cases compared to the controls while @entity227 varied only slightly (p > 0.01). The Amsler grid-test resulted insignificant in our study (p > 0.05). No adverse effects or significant variations in laboratory tests were recorded. CONCLUSION: Further clinical investigations involving larger numbers of @entity1 and a longer follow-up are required to confirm these preliminary results. However, the present study seems to suggest that @entity3791 could be effective in reducing @entity941 -angiographic findings and improving perimetric data in @entity6 with macular @entity4 , even though the mechanism of action remains obscure. @entity227 varied only slightly.
